Welcome to our dedicated page for CapsoVision SEC filings (Ticker: CV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CapsoVision, Inc. filings document a commercial-stage medical technology company focused on AI-enabled capsule endoscopy and gastrointestinal imaging. The company’s SEC record includes registration statements for common stock offerings and resale registration matters, 8-K reports on financial results, private placement financing, material development agreements and FDA-related product updates.
CapsoVision’s proxy materials cover annual meeting voting, board matters and public-company governance. Other disclosures address the company’s capital structure, common stock issuances, executive officer appointments, equity incentive arrangements, indemnification agreements, operating results and development spending tied to CapsoCam Plus®, CapsoCam Colon™ and related imaging technology.
CapsoVision, Inc reported that the Harari Family Trust, for which Eliyahou Harari and his wife serve as trustees, purchased 61,068 shares of common stock on 2026-07-17 at $6.73 per share in an open-market or private transaction, increasing its indirect holdings to 3,343,119 shares.
CapsoVision, Inc insider Harari Eliyahou et al, identified as a ten percent owner, reported an open-market purchase of 81,300 shares of common stock at $6.09 per share on July 8, 2026. The shares are held indirectly through the Harari Family Trust, where the reporting person and spouse serve as trustees, bringing the reported indirect holdings to 3,282,051 shares after this transaction.
CapsoVision, Inc insider holdings increased through an indirect open-market purchase. On June 26, 2026, the Harari Family Trust, for which the reporting person and his wife are trustees, bought 13,850 shares of CapsoVision common stock at $7.351 per share. After this transaction, the trust held 3,200,751 shares in total.
Shields David Stanley reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc director David Stanley Shields received a grant of 1,710 Restricted Stock Units (RSUs). The award was reported at a price of $0.0000 per unit, reflecting a compensation grant rather than a market purchase or sale.
Each RSU represents a contingent right to receive one share of CapsoVision common stock, and these RSUs are scheduled to vest on December 31, 2026. Following this grant, Shields is reported as directly holding 1,710 RSUs linked to common stock.
CapsoVision, Inc director David Stanley Shields filed an initial ownership report on Form 3. The filing indicates that he does not beneficially own any shares of CapsoVision common stock, as confirmed by a footnote stating that no securities are beneficially owned.
CapsoVision, Inc. appointed gastroenterologist Dr. David S. Shields to its Board of Directors as a Class I director and member of the Compensation Committee, effective July 1, 2026, filling the vacancy created by the resignation of Dr. Joanne Imperial.
The Board determined that Dr. Shields is an independent director and he will receive the company’s standard non-employee director compensation and a standard indemnification agreement. Separately, CapsoVision entered into a consulting agreement under which Dr. Shields will provide clinical consulting and industrial affiliation services at US$600 per hour for up to 3 hours per work week.
Dr. Imperial stepped down from the Board and the Compensation Committee, effective July 1, 2026, without any disagreement regarding the company’s operations, policies or practices. Under an amended and restated consulting agreement dated July 2, 2026, she will continue as an independent consultant at US$600 per hour for up to 5 hours per work week and received an option to purchase 10,000 shares of common stock, vesting over four years, as compensation for her services.
CapsoVision, Inc director Joanne Carol Imperial reported a routine equity compensation event. On June 30, she exercised previously granted Restricted Stock Units (RSUs), receiving 2,022 shares of common stock at no cash cost to her as part of an equity incentive grant.
The filing shows she now directly owns 3,709 shares of CapsoVision common stock. The RSU award was originally granted on March 19, 2026 using a fair market value of $6.18 per share, and vests in two installments each year, with this report reflecting the June 30 vesting portion.
CapsoVision, Inc director Joanne Carol Imperial reported an open-market sale of 1,200 shares of Common Stock on June 8, 2026 at an average price of $7.1555 per share. After this transaction, she directly holds 1,687 shares of CapsoVision stock.
The amended Form 4 notes that the filing is being made late because the company was not made aware of the reportable securities sale within the required timeframe.
CapsoVision director Tsai Chen Lung increased his direct equity stake through RSU vesting and option exercise. On June 30, he exercised derivative awards to acquire 2,022 shares of Common Stock at $7.58 per share. These shares came from Restricted Stock Units previously granted as part of equity incentive awards.
The RSUs were granted using a fair market value of $6.18 per share and vest 50% on June 30 and 50% on December 31 of the applicable year. This filing reflects vesting of one-half of the original RSU grant and delivery of the underlying shares. After the transactions, he holds 4,929 Common shares directly and 2,023 RSUs that remain outstanding.
CapsoVision, Inc director Kuo Hui Ying exercised restricted stock units to acquire 2,022 shares of common stock. The RSUs converted at a stated price of $7.58 per share, increasing the director’s direct common stock holdings to 15,263 shares following the transaction.
The RSUs were granted as part of equity incentive awards using a fair market value of $6.18 per share on March 19, 2026. The grant vests 50% of the RSUs on June 30 and 50% on December 31 of the applicable year, and this transaction reflects vesting of one-half of the original grant and receipt of the underlying shares, with 2,023 RSUs remaining outstanding.